XTNT

SEC source: 0001235802-23-000097 · primary_doc.xml · nonDerivative · entry 2

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 494,858

F2 · balance_after: Includes 116,144 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 227,985 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000097 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 520,104

F1 · shares: These shares will vest and be issued with respect to 29,036 shares on each of August 15, 2024, August 15, 2025, August 15, 2026 and August 15, 2027 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes 116,144 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 227,985 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000095 · primary_doc.xml · derivative · entry 3

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,583

Underlying: Common Stock · 140,583 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests with respect to 35,146 shares on August 15, 2024 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-23-000095 · primary_doc.xml · nonDerivative · entry 2

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 774,190

F2 · balance_after: Includes 120,499 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 412,411 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000095 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 824,070

F1 · shares: These shares will vest and be issued with respect to 30,125 shares on each of August 15, 2024, August 15, 2025 and August 15, 2026 and with respect to 30,124 shares on August 15, 2027 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes 120,499 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 412,411 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000096 · primary_doc.xml · derivative · entry 2

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,252

Underlying: Common Stock · 203,252 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests with respect to 50,813 shares on August 15, 2024 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-23-000096 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,680,800

F1 · shares: These shares will vest and be issued with respect to 43,554 shares on each of August 15, 2024, August 15, 2025, August 15, 2026 and August 15, 2027 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes 174,216 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 866,048 shares to be issued upon vesting pursuant to restricted stock awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended from time to time, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000098 · primary_doc.xml · derivative · entry 2

Schallenberger Mark A. · CIK 0001960742 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,501

Underlying: Common Stock · 135,501 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests with respect to 33,875 shares on August 15, 2024 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-23-000098 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,144

F1 · shares: These shares will vest and be issued with respect to 29,036 shares on each of August 15, 2024, August 15, 2025, August 15, 2026 and August 15, 2027 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes 116,144 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 89,000 shares to be issued upon vesting pursuant to a restricted stock award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000094 · primary_doc.xml · derivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,345

Underlying: Common Stock · 42,345 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000094 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,213,125

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 217,770 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000093 · primary_doc.xml · derivative · entry 2

MITCHELL-KELLER LORI D · CIK 0001242852 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,230

Underlying: Common Stock · 28,230 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000093 · primary_doc.xml · nonDerivative · entry 1

MITCHELL-KELLER LORI D · CIK 0001242852 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,962

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest and become issuable on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 145,180 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 45,782 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining a director of Xtant through the vesting dates.

SEC source: 0001235802-23-000091 · primary_doc.xml · derivative · entry 3

Beeson Jonn R. · CIK 0001975134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,230

Underlying: Common Stock · 28,230 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000091 · primary_doc.xml · nonDerivative · entry 1

Beeson Jonn R. · CIK 0001975134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,229

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. 2023 Equity Incentive Plan and 52,049 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining a director of Xtant through the vesting dates.

SEC source: 0001235802-23-000092 · primary_doc.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,230

Underlying: Common Stock · 28,230 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000092 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 591,989

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000090 · primary_doc.xml · derivative · entry 2

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,230

Underlying: Common Stock · 28,230 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000090 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 593,726

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000067 · primary_doc.xml · nonDerivative · entry 1

MITCHELL-KELLER LORI D · CIK 0001242852 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,782

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time), and vest and become issuable on June 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F1 · balance_after: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time), and vest and become issuable on June 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000054 · primary_doc.xml · nonDerivative · entry 1

Beeson Jonn R. · CIK 0001975134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,049

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time), and vest and become issuable on May 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F1 · balance_after: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time), and vest and become issuable on May 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000027 · primary_doc.xml · derivative · entry 2

Schallenberger Mark A. · CIK 0001960742 · Chief Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2033-02-15

F2 · derivative.exercise_date: This option vests with respect to 26,250 shares on February 15, 2024 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-23-000027 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,000

F1 · shares: These shares will vest and be issued with respect to 22,250 shares on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F1 · balance_after: These shares will vest and be issued with respect to 22,250 shares on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-23-000017 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,960

F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6002 to $0.62, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 58,594 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 318,633 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000122 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,995,355

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time, the "2018 Equity Plan"), and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the 2018 Equity Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000114 · primary_doc.xml · nonDerivative · entry 2

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,506,584

F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6017 to $0.6433, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F3 · balance_after: Includes 131,618 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 734,430 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000114 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,557,684

F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6461 to $0.79, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 131,618 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 734,430 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000113 · primary_doc.xml · derivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,214

Underlying: Common Stock · 566,214 shares

Expires 2027-08-25

F3 · security: This warrant was issued in a second and final tranche of a private placement pursuant to the securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors.

F4 · balance_after: This total does not include a warrant to purchase 878,770 shares of common stock issued on August 25, 2022. Such warrant was immediately exercisable as of the date of issuance and previously reported by the Reporting Person on a Form 4 filed with the Securities and Exchange Commission on August 26, 2022.

SEC source: 0001235802-22-000113 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,850,716

F1 · shares: These shares were issued in a second and final tranche of a private placement pursuant to a securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors.

F2 · balance_after: Includes 70,776 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000107 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,585,855

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 70,776 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F3 · balance_after: Includes 3,515,079 shares issued in connection with the first closing of the private placement (the "Private Placement") pursuant to the securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors. Does not include 2,264,861 shares to be issued in connection with the second closing of the Private Placement, which will be issued subject to the satisfaction of certain closing conditions.

SEC source: 0001235802-22-000100 · primary_doc.xml · nonDerivative · entry 3

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,633

F3 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47 to $0.4953, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

F2 · balance_after: Includes 58,594 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 340,878 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000101 · primary_doc.xml · nonDerivative · entry 3

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 703,571

F3 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47 to $0.4953, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

F2 · balance_after: Includes 588,046 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000100 · primary_doc.xml · nonDerivative · entry 2

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 413,903

F3 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47161 to $0.517084, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · balance_after: Includes 58,594 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 340,878 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000101 · primary_doc.xml · nonDerivative · entry 2

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 707,871

F3 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47161 to $0.52, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · balance_after: Includes 588,046 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000096 · primary_doc.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 215,415

F5 · kind: This restricted stock unit award was granted to Rizzo, a director of Xtant.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo ("Rizzo") remaining a director of Xtant through the vesting date.

F2 · balance_after: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo ("Rizzo") remaining a director of Xtant through the vesting date.

F3 · ownership.nature: See Exhibit 99.1.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of OrbiMed Advisors and ROF II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated certain representatives, including Rizzo and Eggenberg, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-22-000096 · primary_doc.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 215,415

F1 · kind: This restricted stock unit award was granted to Michael Eggenberg ("Eggenberg"), a director of Xtant Medical Holdings, Inc. ("Xtant").

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo ("Rizzo") remaining a director of Xtant through the vesting date.

F2 · balance_after: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo ("Rizzo") remaining a director of Xtant through the vesting date.

F3 · ownership.nature: See Exhibit 99.1.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of OrbiMed Advisors and ROF II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated certain representatives, including Rizzo and Eggenberg, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-22-000100 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 419,003

F1 · shares: These shares will vest and be issued with respect to 62,974 shares on each of August 15, 2023, August 15, 2024, and August 15, 2025 and with respect to 62,973 shares on August 15, 2026 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date

F2 · balance_after: Includes 58,594 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 340,878 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000101 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 726,571

F1 · shares: These shares will vest and be issued with respect to 102,520 shares on each of August 15, 2023, August 15, 2024 and August 15, 2025 and with respect to 102,519 shares on August 15, 2026 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

F2 · balance_after: Includes 588,046 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-22-000099 · primary_doc.xml · nonDerivative · entry 1

Peters Jeffrey J · CIK 0001329814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 448,546

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2023, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000098 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,809

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2023, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000097 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 448,546

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000095 · primary_doc.xml · nonDerivative · entry 1

Eggenberg Michael · CIK 0001732521 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,415

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F1 · balance_after: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: The Reporting Person's Form 4 report filed on August 17, 2021 previously reported 120,549 shares that were subject to unvested restricted stock unit awards. These shares have vested and were transferred to each of ROS Acquisition Offshore LP ("ROS Acquisition") and OrbiMed Royalty Opportunities II, LP ("ORO II").

SEC source: 0001235802-22-000094 · primary_doc.xml · nonDerivative · entry 1

Rizzo Matthew · CIK 0001732511 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,415

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F1 · balance_after: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: The Reporting Person's Form 4 report filed on August 17, 2021 previously reported 120,549 shares that were subject to unvested restricted stock unit awards. These shares have vested and were transferred to each of ROS Acquisition Offshore LP ("ROS Acquisition") and OrbiMed Royalty Opportunities II, LP ("ORO II").

SEC source: 0001235802-22-000017 · primary_doc.xml · derivative · entry 2

Neils Scott C · CIK 0001902610 · Interim Chief Financial Office

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,164

Underlying: Common Stock · 109,164 shares

Expires 2032-01-15

F3 · derivative.exercise_date: This option vests with respect to 27,291 shares on January 15, 2023 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

SEC source: 0001235802-22-000017 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Interim Chief Financial Office

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,108

F1 · shares: These shares will vest and be issued with respect to 22,246 shares on each of January 15, 2023, January 15, 2024, and January 15, 2025 and with respect to 22,245 shares on January 15, 2026 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes 78,125 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 88,983 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-21-000129 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,637,684

F1 · balance_after: Includes 197,426 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 1,101,644 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.

SEC source: 0001235802-21-000109 · primary_doc.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 120,549

F4 · kind: See Exhibit 99.2.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

F4 · ownership.nature: See Exhibit 99.2.

SEC source: 0001235802-21-000109 · primary_doc.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 120,549

F1 · kind: See Exhibit 99.1.

F2 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F2 · balance_after: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F1 · ownership.nature: See Exhibit 99.1.

F3 · ownership.nature: This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.

SEC source: 0001235802-21-000108 · primary_doc.xml · derivative · entry 3

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,519

Underlying: Common Stock · 199,519 shares

Expires 2031-08-15

F3 · derivative.exercise_date: This option vests with respect to 49,879 shares on August 15, 2021 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.

SEC source: 0001235802-21-000108 · primary_doc.xml · nonDerivative · entry 2

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 316,492

F2 · balance_after: Includes 251,081 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan.